If the company stays alive, we will find out eventually more about enrollment. Best case if 80 enrolled by end of June, maybe end of 2019 for end of trial, then end of 2020 for actual approval.
I see no path for shortcuts, good that those FDA around the corner posts are in decline. 2019 has a chance to be a good year for the stock, but at least through March 2019 there might be appalling, really appalling levels of dilution
News 
Market Data 
Discover 
